Skip to main content
Equibles
BVS logo

BVS · Bioventus Inc. · Metrics

Track BVS — free

Use BVS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BVS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$14.96 -0.08 (-0.53%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$1.26B
Shares
84.09M
Volume · Oct 23 387.05K Avg daily vol (3M) 583.02K

BVS metrics

102 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$14.96
Market cap
$1.26B

Price action

20 metrics
Price change (1W)
+12.5%
Price change (30D)
+8.3%
Price change (3M)
+26.8%
Price change (6M)
+48.3%
Price change (YTD)
+101.1%
Price change (1Y)
+114.9%
Trailing year
Price change (5Y)
-2.1%
52-week high
$15.26
52-week low
$6.53
Change from 52-week high
-2.0%
Change from 52-week low
+129.1%
Annualized volatility
51.1%
Annualized volatility (3M)
49.1%
Beta
0.6
RSI (14D)
65.9
Price vs SMA 50
+9.2%
Price vs SMA 200
+39.3%
Avg volume (3M)
583,024
Relative volume
0.7
Average dollar volume
$8.02M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
84.09M

Valuation

12 metrics
P / E (TTM)
19.4
Trailing earnings · reciprocal yield 5.1%
PEG ratio
0.1
EV / revenue
2.5×
reciprocal yield 39.4%
EV / EBITDA
14.2×
reciprocal yield 7.1%
EV / EBIT
25.3×
reciprocal yield 3.9%
P / sales
2.2×
reciprocal yield 46.3%
P / book
5.5
reciprocal yield 18.1%
FCF yield
7.5%
TTM · current market cap
Buyback yield
—
P / FCF
13.3
reciprocal yield 7.5%
P / operating cash flow
13.0
reciprocal yield 7.7%
Earnings yield
4.3%

Historical valuation

8 metrics
P / E historical average (3Y)
72.8×
reciprocal yield 1.4%
P / E historical average (5Y)
72.8×
reciprocal yield 1.4%
EV / revenue historical average (3Y)
1.8×
reciprocal yield 56.8%
EV / revenue historical average (5Y)
1.7×
reciprocal yield 57.5%
EV / EBIT historical average (3Y)
26.3×
reciprocal yield 3.8%
EV / EBIT historical average (5Y)
38.9×
reciprocal yield 2.6%
EV / EBITDA historical average (3Y)
21.5×
reciprocal yield 4.7%
EV / EBITDA historical average (5Y)
28.1×
reciprocal yield 3.6%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
68.7%
Operating margin
10.0%
Trailing 12 months
Net margin
9.4%
Gross profit (TTM)
$399.45M
Operating profit (TTM)
$58.28M
Net income (TTM)
$54.46M
Trailing 12 months
Diluted EPS (TTM)
$0.77
FCF margin
16.2%
Effective tax rate
-59.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$8.26
Gross profit per diluted share (TTM)
$5.67
Operating profit per diluted share (TTM)
$0.82
EBITDA per diluted share (TTM)
$1.47
Net income per diluted share (TTM)
$0.77
Operating cash flow per diluted share (TTM)
$1.37
Free cash flow per diluted share (TTM)
$1.34
Capital expenditures per diluted share (TTM)
$0.04
R&D per diluted share (TTM)
$0.16
Stock compensation per diluted share (TTM)
$0.21
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+3.8%
Year over year
Net income growth YoY
+348.3%
Revenue (TTM)
$581.85M
Trailing 12 months
EPS growth YoY
+327.3%
Shares change YoY
+3.4%
Year over year · more shares
Revenue CAGR (3Y)
+3.5%
Revenue CAGR (5Y)
+12.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+5.5%

Quality

14 metrics
Return on equity
23.9%
Return on assets
8.1%
Debt / equity
1.1
Current ratio
1.7
EBITDA (TTM)
$104.23M
Free cash flow (TTM)
$94.29M
Quick ratio
1.2
Interest coverage
—
Net debt / EBITDA
2.1
Return on invested capital
—
Trailing 12 months
Net cash
−$219.00M
Latest balance sheet
Cash & equivalents
$29.46M
Total assets
$673.35M
Total debt
$248.45M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$96.87M
Capital expenditures (TTM)
$2.59M
R&D (TTM)
$11.57M
SG&A (TTM)
$322.48M
Stock compensation (TTM)
$14.92M
R&D / revenue
2.0%
Stock compensation / revenue
2.6%

Ownership (13F)

9 metrics
13F filers
157
13F filer change QoQ
0
Institutional ownership
64.3%
Conviction holders (share of 13F filers)
1.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+5.2%
Holder tenure
14.5
Price vs estimated holder cost
+3.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.7%

Short interest

3 metrics
Short interest
3.8%
Latest settlement · 6.7 days to cover
Days to cover
6.7d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1665988 CUSIP 09075A108 13F (30d) 21 filings 21 filers Visit website Investor relations